Last reviewed · How we verify

NCT01573897: SAS-FOOT

Impact of Sleep Apnea on Diabetic Foot Wound.

Terminated Last updated 28 June 2018
What this trial tests

trial in Diabetic Foot in 35 participants. Terminated before completion.

Timeline
4 June 2012
Primary endpoint
15 November 2016
15 November 2016

Quick facts

Lead sponsorAGIR à Dom
StatusTerminated
Study typeOBSERVATIONAL
Enrollment35
Start date4 June 2012
Primary completion15 November 2016
Estimated completion15 November 2016
Sites1 location across France

Conditions studied

Sponsor

AGIR à Dom

Who can join

18 and older, any sex, with Diabetic Foot or Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sleep apnea syndrome (SAS) is a common comorbidity of type 1 and type 2 diabetes. A low transcutaneous oxygen tension (PtcO2) measured on the foot is pejorative prognostic factor for the healing of a diabetic foot wound. SAS causes intermittent nocturnal hypoxia and sympathetic overactivity. The investigators hypothesized that SAS could be a factor reducing the PtcO2.Therefore, the main objective of this study is to assess the variation in PtcO2 between the end of the night and midday in patients with -or at risk of- diabetic foot wound according to the presence or not of sleep apnea syndrome.The secondary objective is to address the microvascularisation of diabetic patients having foot wounds according to their status regarding sleep apnea syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Foot

Currently open trials in the same condition.

Other AGIR à Dom trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01573897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing